Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.38 |
| ▸ | TLR2 | O60603 | 3/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.33 |
| ▸ | CHRNG | P07510 | 2/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.33 |
| ▸ | CHRND | Q07001 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22566714 | 0.96 | GLP1R (0.44) | GLP1RLPAR3TLR2LPAR1MEN1 | |
| SCHEMBL20017564 | 0.89 | GLP1R (0.46) | GLP1RLPAR3TLR2LPAR1MEN1 | |
| SCHEMBL21287416 | 0.89 | GLP1R (0.54) | GLP1RLPAR3TLR2LPAR1CHRNA1 | |
| SCHEMBL21287433 | 0.89 | GLP1R (0.46) | GLP1RLPAR3TLR2LPAR1MEN1 | |
| SCHEMBL20375472 | 0.86 | GLP1R (0.46) | GLP1RLPAR3TLR2LPAR1MEN1 | |
| SCHEMBL20375605 | 0.85 | GLP1R (0.47) | GLP1RLPAR3TLR2LPAR1MEN1 | |
| SCHEMBL22566694 | 0.85 | GLP1R (0.44) | GLP1RLPAR3TLR2LPAR1MEN1 | |
| SCHEMBL23714584 | 0.84 | GLP1R (0.46) | GLP1RLPAR3TLR2LPAR1MEN1 | |
| SCHEMBL21498217 | 0.84 | GLP1R (0.44) | GLP1RLPAR3TLR2LPAR1MEN1 | |
| SCHEMBL22172474 | 0.82 | GLP1R (0.41) | GLP1RLPAR3TLR2LPAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11492624-B2 | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 | Arrowheads Pharmaceuticals, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-12-30 | — | — | US | disclosed |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210100829-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-04-08 | — | — | US | disclosed |
| US-20200283777-A1 | RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1 | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-09-10 | — | — | US | disclosed |
| US-20200263179-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-08-20 | — | — | US | disclosed |
| US-10597657-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Arrowhead Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | Arrowhead Pharmaceuticals, Inc. | 2019-12-19 | — | — | US | disclosed |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190078088-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885TLR2 1481/4885 |
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885TLR2 1481/4885 |
| US-11492624-B2 | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 | ASGR1, LDLR, SCARB1 | GLP1R 217/4885LPAR3 150/4885TLR2 712/4885 |
| US-20190078088-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885LPAR3 205/4885TLR2 2801/4885 |
| US-10597657-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885LPAR3 205/4885TLR2 2801/4885 |
| US-20210100829-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885TLR2 1481/4885 |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, NR1H4 | GLP1R 3941/4885LPAR3 559/4885TLR2 1488/4885 |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | HAVCR2, EIF2AK2, HDGF | GLP1R 4794/4885LPAR3 860/4885TLR2 3462/4885 |
| US-20200283777-A1 | RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1 | ASGR1, LDLR, SCARB1 | GLP1R 405/4885LPAR3 125/4885TLR2 1013/4885 |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885TLR2 1481/4885 |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | F12, F13A1, F13B | GLP1R 4018/4885LPAR3 842/4885TLR2 4753/4885 |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885TLR2 1481/4885 |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885LPAR3 3281/4885TLR2 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.